Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Total Neoadjuvant Therapy for Locally Advanced Gastric Cancer
NCT04062058Phase 2Unknown
- Start
- Nov 2019
- Primary completion
- Sep 2022
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tegafur and oxaliplatin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma. Primary endpoint: Pathologic Complete Response rate. Status: unknown.
02
Drugs
tegafuroxaliplatin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04062058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04062058.